Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly transmittable pathogenic viral infection that causes a disease known as COVID-19. It is a pandemic and public health challenge ravaging the world today. Unfortunately, with the daily increase of infected individuals, there is no known drug approved for the treatment of COVID-19. However, there are therapeutic drugs with the potentials to inhibit endocytic pathways, suppress ribonucleic acid (RNA) polymerase activities, and reduce the replication of SARS-CoV-2. These drugs modifications are aimed at reducing inflammation, time of recovery, and number of deaths. This review is aimed at providing updated information on the clinical manifestations, diagnosis, preventive measures and therapeutic drugs used against SARS-CoV-2. The finding of this review revealed that some of these drugs are transmembrane protease, serine 2, and angiotensin-converting enzyme 2 inhibitors with the capacity to block the entrance/replication of SARS-CoV-2 in a host cell and therefore, may be promising in preventing the spread and mortality of SARS-CoV-2. However, these drugs may cause detrimental health effects such as toxic and non-efficacy issues. Therefore great caution should be employed by health professionals when prescribing these drugs to COVID-19 patients.
Research funding: None declared.
Author contributions: Eleazer U. Ikonne: Conceptualization, resources, writing original draft and editing; Victor O. Ikpeazu: Conceptualization, data curation, methodology and editing; Ositadinma C. Ugbogu: writing original draft and editing; Okezie Emmanuel: Methodology, original draft and editing; Ikechukwu P. Nwakuche; Conceptualization, original draft and editing; Emeka J. Iweala: writing original draft and editing; Eziuche A. Ugbogu: Conceptualization, resources, original draft and editing. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
References
1. Tripathy, S, Dassarma, B, Roy, S, Chabalala, H, Matsabisa, MG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents 2020;56:106028. https://doi.org/10.1016/j.ijantimicag.2020.106028.Search in Google Scholar PubMed PubMed Central
2. Jodele, S, Köhl, J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol 2020. https://doi.org/10.1111/bph.15187 [Epub ahead of print].Search in Google Scholar PubMed PubMed Central
3. Gupta, A, Madhavan, MV, Sehgal, K, Nair, N, Mahajan, S, Sehrawat, TS, et al.. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26:1017–32. https://doi.org/10.1038/s41591-020-0968-3.Search in Google Scholar PubMed
4. Gao, J, Tian, Z, Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3. https://doi.org/10.5582/bst.2020.01047.Search in Google Scholar PubMed
5. Risitano, AM, Mastellos, DC, Huber-Lang, M, Yancopoulou, D, Garlanda, C, Ciceri, F, et al.. Complement as a target in COVID-19? Nat Rev Immunol 2020;20:343–4. https://doi.org/10.1038/s41577-020-0320-7.Search in Google Scholar PubMed PubMed Central
6. Gattinoni, L, Coppola, S, Cressoni, M, Busana, M, Rossi, S, Chiumello, D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;201:1299–300. https://doi.org/10.1164/rccm.202003-0817LE.Search in Google Scholar PubMed PubMed Central
7. Magro, C, Mulvey, JJ, Berlin, D, Nuovo, G, Salvatore, S, Harp, J, et al.. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020;220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007.Search in Google Scholar PubMed PubMed Central
8. Dong, L, Hu, S, Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58–60. https://doi.org/10.5582/ddt.2020.01012.Search in Google Scholar PubMed
9. Setti, L, Passarini, F, De Gennaro, G, Barbieri, P, Perrone, MG, Borelli, M, et al.. Airborne transmission route of COVID-19: why 2 meters/6 feet of inter-personal distance could not be enough. Int J Environ Res Publ Health 2020;17:2932. https://doi.org/10.3390/ijerph17082932.Search in Google Scholar PubMed PubMed Central
10. Rana, DR, Dulal, S. Therapeutic application of chloroquine and hydroxychloro-quine in clinical trials for COVID-19: a systematic review. medRxiv 2020. https://doi.org/10.1101/2020.03.22.20040964 [Epub ahead of print].Search in Google Scholar
11. Zhou, D, Dai, SM, Tong, Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75:1667–70. https://doi.org/10.1093/jac/dkaa114.Search in Google Scholar
12. Gautret, P, Lagier, JC, Parola, P, Hoang, VT, Meddeb, L, Mailhe, M, et al.. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.Search in Google Scholar
13. Shamseer, L, Moher, D, Clarke, M, Ghersi, D, Liberati, A, Petticrew, M, et al.. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647. https://doi.org/10.1136/bmj.g7647.Search in Google Scholar
14. Lauer, SA, Grantz, KH, Bi, Q, Jones, FK, Zheng, Q, Meredith, HR, et al.. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577–82. https://doi.org/10.7326/M20-0504.Search in Google Scholar
15. Wang, Z, Yang, B, Li, Q, Wen, L, Zhang, R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:769–77. https://doi.org/10.1093/cid/ciaa272.Search in Google Scholar
16. Rothe, C, Schunk, M, Sothmann, P, Bretzel, G, Froeschl, G, Wallrauch, C, et al.. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970–71. https://doi.org/10.1056/NEJMc2001468.Search in Google Scholar
17. Pooladanda, V, Thatikonda, S, Godugu, C. The current understanding and potential therapeutic options to combat COVID-19. Life Sci 2020;254:117765. https://doi.org/10.1016/j.lfs.2020.117765.Search in Google Scholar
18. Huang, C, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.Search in Google Scholar
19. Huang, F, Li, Y, Leung, EL, Liu, X, Liu, K, Wang, Q, et al.. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res 2020;158:104929. https://doi.org/10.1016/j.phrs.2020.104929.Search in Google Scholar PubMed PubMed Central
20. Rothan, HA, Byrareddy, SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433.Search in Google Scholar PubMed PubMed Central
21. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) 2020. Mission-oncovid-19-final-report.pdf. 1–40 pp., Available from: https://intensiveblog.com/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-covid-19/ [Accessed 17 Oct 2020].Search in Google Scholar
22. CDC. Coronavirus disease 2019 (COVID-19): steps to prevent illness. Centers for disease control and prevention 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html [Accessed 20 Sep 2020].Search in Google Scholar
23. Abduljalil, JM. Laboratory diagnosis of SARS-CoV-2: available approaches and limitations. New Microbes New Infect 2020;36:100713. https://doi.org/10.1016/j.nmni.2020.100713.Search in Google Scholar PubMed PubMed Central
24. Zhang, N, Wang, L, Deng, X, Liang, R, Su, M, He, C, et al.. Recent advances in the detection of respiratory virus infection in humans. J Med Virol 2020;92:408–17. https://doi.org/10.1002/jmv.25674.Search in Google Scholar PubMed PubMed Central
25. Kumar, R, Nagpal, S, Kaushik, S, Mendiratta, S. COVID-19 diagnostic approaches: different roads to the same destination. VirusDisease 2020;31:97–105. https://doi.org/10.1007/s13337-020-00599-7.Search in Google Scholar PubMed PubMed Central
26. Chu, DKW, Pan, Y, Cheng, SMS, Hui, KPY, Krishnan, P, Liu, Y, et al.. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020;66:549–55. https://doi.org/10.1093/clinchem/hvaa029.Search in Google Scholar PubMed PubMed Central
27. Corman, VM, Landt, O, Kaiser, M, Molenkamp, R, Meijer, A, Chu, DK, et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.Search in Google Scholar PubMed PubMed Central
28. To, KK, Tsang, OT, Yip, CC, Chan, KH, Wu, TC, Chan, JM, et al.. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020;71:841–3. https://doi.org/10.1093/cid/ciaa149.Search in Google Scholar PubMed PubMed Central
29. Chung, M, Bernheim, A, Mei, X, Zhang, N, Huang, M, Zeng, X, et al.. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020;295:202–7. https://doi.org/10.1148/radiol.2020200230.Search in Google Scholar PubMed PubMed Central
30. Nguyen, T, Duong Bang, D, Wolff, A. 2019 novel coronavirus disease (covid-19): paving the road for rapid detection and point-of-care diagnostics. Micromachines 2020;11:306. https://doi.org/10.3390/mi11030306.Search in Google Scholar PubMed PubMed Central
31. Cortegiani, A, Ingoglia, G, Ippolito, M, Giarratano, A, Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279–83. https://doi.org/10.1016/j.jcrc.2020.03.005.Search in Google Scholar PubMed PubMed Central
32. FDA. Memorandum explaining basis for revocation of emergency use authorization for emergency use of chloroquine phosphate and hydroxychloroquine sulfate 2020. Available from: https://www.fda.gov/media/138945/download [Accessed 14 Oct 2020].Search in Google Scholar
33. Tu, YF, Chien, CS, Yarmishyn, AA, Lin, YY, Luo, YH, Lin, YT, et al.. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020;21:2657. https://doi.org/10.3390/ijms21072657.Search in Google Scholar PubMed PubMed Central
34. Pandey, A, Nikam, AN, Shreya, AB, Mutalik, SP, Gopalan, D, Kulkarni, S, et al.. Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements. Life Sci 2020;256:117883. https://doi.org/10.1016/j.lfs.2020.117883.Search in Google Scholar PubMed PubMed Central
35. Devaux, CA, Rolain, JM, Colson, P, Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;55:105938. https://doi.org/10.1016/j.ijantimicag.2020.105938.Search in Google Scholar PubMed PubMed Central
36. Colson, P, Rolain, JM, Lagier, JC, Brouqui, P, Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55:105932. https://doi.org/10.1016/j.ijantimicag.2020.105932.Search in Google Scholar PubMed PubMed Central
37. Yu, B, Li, C, Chen, P, Zhou, N, Wang, L, Li, J, et al.. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci 2020;63:1515–21. https://doi.org/10.1007/s11427-020-1732-2.Search in Google Scholar PubMed PubMed Central
38. Arshad, S, Kilgore, P, Chaudhry, ZS, Jacobsen, G, Wang, DD, Huitsing, K, et al.. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020;97:396–403. https://doi.org/10.1016/j.ijid.2020.06.099.Search in Google Scholar PubMed PubMed Central
39. Geleris, J, Sun, Y, Platt, J, Zucker, J, Baldwin, M, Hripcsak, G, et al.. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382:2411–8.10.1056/NEJMoa2012410Search in Google Scholar PubMed PubMed Central
40. Chen, J, Liu, D, Liu, L, Liu, P, Xu, Q, Xia, L, et al.. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49:215–9. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03.Search in Google Scholar PubMed PubMed Central
41. Tang, W, Cao, Z, Han, M, Wang, Z, Chen, J, Sun, W, et al.. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.Search in Google Scholar PubMed PubMed Central
42. Lopez, A, Duclos, G, Pastene, B, Bezulier, K, Guilhaumou, R, Solas, C, et al.. Effects of hydroxychloroquine on covid-19 in intensive care unit patients: preliminary results. Int J Antimicrob Agents 2020;56:106136. https://doi.org/10.1016/j.ijantimicag.2020.106136.Search in Google Scholar PubMed PubMed Central
43. Magagnoli, J, Narendran, S, Pereira, F, Cummings, T, Hardin, JW, Sutton, SS, et al.. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020. https://doi.org/10.1101/2020.04.16.20065920 [Epub ahead of print].Search in Google Scholar PubMed PubMed Central
44. Molina, JM, Delaugerre, C, Le Goff, J, Mela-Lima, B, Ponscarme, D, Goldwirt, L, et al.. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Maladies Infect 2020;50:384. https://doi.org/10.1016/j.medmal.2020.03.006.Search in Google Scholar PubMed PubMed Central
45. Boulware, DR, Pullen, MF, Bangdiwala, AS, Pastick, KA, Lofgren, SM, Okafor, EC, et al.. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383:517–25. https://doi.org/10.1056/NEJMoa2016638.Search in Google Scholar PubMed PubMed Central
46. Huang, M, Tang, T, Pang, P, Li, M, Ma, R, Lu, J, et al.. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020;12:322–5. https://doi.org/10.1093/jmcb/mjaa014.Search in Google Scholar PubMed PubMed Central
47. Borba, MG, Val, FF, Sampaio, VS, Alexandre, MA, Melo, GC, Brito, M, et al.. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020;3:e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857.Search in Google Scholar PubMed
48. Schwartz, RA, Suskind, RM. Azithromycin and COVID-19: prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther 2020;33:e13785. https://doi.org/10.1111/dth.13785.Search in Google Scholar PubMed PubMed Central
49. Voisin, O, Lorc’h, EL, Mahé, A, Azria, P, Borie, MF, Hubert, S, et al.. Acute QT interval modifications during hydroxychloroquine-azithromycin treatment in the context of COVID-19 infection. Mayo Clin Proc 2020;95:1696–700. https://doi.org/10.1016/j.mayocp.2020.05.005.Search in Google Scholar PubMed PubMed Central
50. Lagier, JC, Million, M, Gautret, P, Colson, P, Cortaredona, S, Giraud-Gatineau, A, et al.. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Trav Med Infect Dis 2020;36:101791. https://doi.org/10.1016/j.tmaid.2020.101791.Search in Google Scholar PubMed PubMed Central
51. Derwand, R, Scholz, M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Med Hypotheses 2020;142:109815. https://doi.org/10.1016/j.mehy.2020.109815.Search in Google Scholar PubMed PubMed Central
52. Million, M, Lagier, JC, Gautret, P, Colson, P, Fournier, PE, Amrane, S, et al.. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1,061 cases in Marseille, France. Trav Med Infect Dis 2020;35:101738. https://doi.org/10.1016/j.tmaid.2020.101738.Search in Google Scholar PubMed PubMed Central
53. O’Connell, TF, Bradley, CJ, Abbas, AE, Williamson, BD, Rusia, A, Tawney, AM, et al.. Hydroxychloroquine/azithromycin therapy and qt prolongation in hospitalized patients with COVID-19. JACC Clin Electrophysiol 2020. https://doi.org/10.1016/j.jacep.2020.07.016 [Epub ahead of print].Search in Google Scholar PubMed PubMed Central
54. Chorin, E, Wadhwani, L, Magnani, S, Dai, M, Shulman, E, Nadeau-Routhier, C, et al.. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm 2020;17:1425–33. https://doi.org/10.1016/j.hrthm.2020.05.014.Search in Google Scholar
55. McKee, DL, Sternberg, A, Stange, U, Laufer, S, Naujokat, C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020;157:104859. https://doi.org/10.1016/j.phrs.2020.104859.Search in Google Scholar
56. Al-Tawfiq, JA, Al-Homoud, AH, Memish, ZA. Remdesivir as a possible therapeutic option for the COVID-19. Trav Med Infect Dis 2020;34:101615. https://doi.org/10.1016/j.tmaid.2020.101615.Search in Google Scholar
57. Sheahan, TP, Sims, AC, Leist, SR, Schäfer, A, Won, J, Brown, AJ, et al.. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222. https://doi.org/10.1038/s41467-019-13940-6.Search in Google Scholar
58. Grein, J, Ohmagari, N, Shin, D, Diaz, G, Asperges, E, Castagna, A, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327–36. https://doi.org/10.1056/NEJMoa2007016.Search in Google Scholar
59. Beigel, JH, Tomashek, KM, Dodd, LE, Mehta, AK, Zingman, BS, Kalil, AC, et al.. Remdesivir for the treatment of Covid-19 – Final report. N Engl J Med 2020;383:1813–26. https://doi.org/10.1056/NEJMoa2007764.Search in Google Scholar
60. Goldman, JD, Lye, DCB, Hui, DS, Marks, KM, Bruno, R, Montejano, R, et al.. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383:1827–37. https://doi.org/10.1056/NEJMoa2015301.Search in Google Scholar
61. Antinori, S, Cossu, MV, Ridolfo, AL, Rech, R, Bonazzetti, C, Pagani, G, et al.. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res 2020;158:104899. https://doi.org/10.1016/j.phrs.2020.104899.Search in Google Scholar
62. Dubert, M, Visseaux, B, Isernia, V, Bouadma, L, Deconinck, L, Patrier, J, et al.. Case report study of the first five COVID-19 patients treated with remdesivir in France. Int J Infect Dis 2020;98:290–93. https://doi.org/10.1016/j.ijid.2020.06.093.Search in Google Scholar
63. Wang, Y, Zhang, D, Du, G, Du, R, Zhao, J, Jin, Y, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9.Search in Google Scholar
64. Li, Y, Xie, Z, Lin, W, Cai, W, Wen, C, Guan, Y, et al.. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Medicine 2020;1:105–13. https://doi.org/10.1016/j.medj.2020.04.001.Search in Google Scholar
65. Cao, B, Wang, Y, Wen, D, Liu, W, Wang, J, Fan, G, et al.. Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787–99. https://doi.org/10.1056/NEJMoa2001282.Search in Google Scholar
66. Ampel, NM. Lopinavir-ritonavir was not effective for COVID-19. NEJM J Watch 2020. https://doi.org/10.1056/nejm-jw.NA51172 [Epub ahead of print].Search in Google Scholar
67. Hung, IF, Lung, KC, Tso, EY, Liu, R, Chung, TW, Chu, MY, et al.. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695–704. https://doi.org/10.1016/S0140-6736(20)31042-4.Search in Google Scholar
68. Yan, D, Liu, XY, Zhu, YN, Huang, L, Dan, BT, Zhang, GJ, et al.. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J 2020;56:2000799. https://doi.org/10.1183/13993003.00799-2020.Search in Google Scholar PubMed PubMed Central
69. Deng, L, Li, C, Zeng, Q, Liu, X, Li, X, Zhang, H, et al.. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect 2020;81:1–5. https://doi.org/10.1016/j.jinf.2020.03.002.Search in Google Scholar PubMed PubMed Central
70. Liu, X, Chen, H, Shang, Y, Zhu, H, Chen, G, Chen, Y, et al.. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials 2020;21:622. https://doi.org/10.1186/s13063-020-04478-w.Search in Google Scholar PubMed PubMed Central
71. Klement-Frutos, E, Burrel, S, Peytavin, G, Marot, S, Lê, MP, Godefroy, N, et al.. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. J Infect 2020;82:159–98. https://doi.org/10.1016/j.jinf.2020.05.039.Search in Google Scholar PubMed PubMed Central
72. Young, BE, Ong, SWX, Kalimuddin, S, Low, JG, Tan, SY, Loh, J, et al.. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. J Am Med Assoc 2020;323:1488–94. https://doi.org/10.1001/jama.2020.3204.Search in Google Scholar PubMed PubMed Central
73. Wu, R, Wang, L, Kuo, HD, Shannar, A, Peter, R, Chou, PJ, et al.. An update on current therapeutic drugs treating covid-19. Curr Pharmacol Rep 2020:1–15. https://doi.org/10.1007/s40495-020-00216-7 [Epub ahead of print].Search in Google Scholar PubMed PubMed Central
74. Javorac, D, Grahovac, L, Manić, L, Stojilković, N, Anđelković, M, Bulat, Z, et al.. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. Food Chem Toxicol 2020;144:111639. https://doi.org/10.1016/j.fct.2020.111639.Search in Google Scholar
75. Zhu, Z, Lu, Z, Xu, T, Chen, C, Yang, G, Zha, T, et al.. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020;81:21–3. https://doi.org/10.1016/j.jinf.2020.03.060.Search in Google Scholar
76. Lian, N, Xie, H, Lin, S, Huang, J, Zhao, J, Lin, Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 2020;26:917–21. https://doi.org/10.1016/j.cmi.2020.04.026.Search in Google Scholar
77. Cai, Q, Yang, M, Liu, D, Chen, J, Shu, D, Xia, J, et al.. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020;6:1192–8. https://doi.org/10.1016/j.eng.2020.03.007.Search in Google Scholar
78. Tong, S, Su, Y, Yu, Y, Wu, C, Chen, J, Wang, S, et al.. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 2020;56:106114. https://doi.org/10.1016/j.ijantimicag.2020.106114.Search in Google Scholar
79. Hirota, M, Shimosegawa, T, Kitamura, K, Takeda, K, Takeyama, Y, Mayumi, T, et al.. Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. J Gastroenterol 2020;55:342–52. https://doi.org/10.1007/s00535-019-01644-z.Search in Google Scholar
80. Doi, K, Ikeda, M, Hayase, N, Moriya, K, Morimura, N, COVID-UTH Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care 2020;24:392. https://doi.org/10.1186/s13054-020-03078-z.Search in Google Scholar
81. Chan, JF, Yuan, S, Kok, KH, To, KK, Chu, H, Yang, J, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23. https://doi.org/10.1016/S0140-6736(20)30154-9.Search in Google Scholar
82. Mercuro, NJ, Yen, CF, Shim, DJ, Maher, TR, McCoy, CM, Zimetbaum, PJ, et al.. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1036–41. https://doi.org/10.1001/jamacardio.2020.1834.Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
